Pharmiweb.com RSS Feeds 
PharmiWeb Candidate Blog
Press Release
Dendreon to Host Conference Call on May 7 to Announce First Quarter Financial Results and Webcast Presentations at Upcoming Conferences
Dendreon CorporationPosted on:10 Apr 12April 9, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced that management will host a conference call on Monday, May 7, 2012, at 4:30 p.m. EDT to review first quarter financial results.
Access to the discussion may be obtained as follows:
| Time: | Â | 4:30 p.m. EDT / 1:30 p.m. PDT |
| Date: | May 7, 2012 | |
| Dial-in: | 1-877-548-9590 (domestic) or +1-720-545-0037 (international); | |
| conference pass code: 70198839 | ||
| Webcast: | www.dendreon.com (homepage and investor relations section) | |
| Â |
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-800-585-8367 or +1-404-537-3406 for international callers; the conference ID number is 70198839. The replay will be available from 7:30 p.m. EDT on Monday, May 7, until 11:59 p.m. EDT on Monday, May 14. In addition, the webcast will be archived for on-demand listening for 90 days at www.dendreon.com.
Dendreon Corporation also announced that management will present at the following conferences:
- Deutsche Bank Securities 37th Annual Health Care Conference in Boston, MA, on May 8, 2012, at 8:00 a.m. EDT
- Baird’s 2012 Growth Stock Conference in Chicago, IL, on May 9, 2012, at 11:15 a.m. CDT
- Bank of America Merrill Lynch 2012 Health Care Conference in Las Vegas, NV, on May 16 at 5:00 p.m. PDT
The presentations will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcasts, they will be archived on the site following the presentation. To access the replays, go to the Investor Relations section of the website.
About Dendreon
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.
Business Wirehttp://www.businesswire.com/
Last updated on: 10/04/2012 08:00:02
